The Stat3/5 Signaling Biosignature in Hematopoietic Stem/Progenitor Cells Predicts Response and Outcome in Myelodysplastic Syndrome Patients Treated with AzacitidineParaskevi Miltiades, Ιoannis Kotsianidis, Eleftheria Lamprianidou et al.|Clinical Cancer Research|2015Cited by 18
Supplementary Table S2 from The Stat3/5 Signaling Biosignature in Hematopoietic Stem/Progenitor Cells Predicts Response and Outcome in Myelodysplastic Syndrome Patients Treated with AzacitidineParaskevi Miltiades, Ιoannis Kotsianidis, Eleftheria Lamprianidou et al.|Unknown|2023Cited by 0
Supplementary Figure S5 from The Stat3/5 Signaling Biosignature in Hematopoietic Stem/Progenitor Cells Predicts Response and Outcome in Myelodysplastic Syndrome Patients Treated with AzacitidineParaskevi Miltiades, Ιoannis Kotsianidis, Eleftheria Lamprianidou et al.|Unknown|2023Cited by 0
Supplementary Figure S1 from The Stat3/5 Signaling Biosignature in Hematopoietic Stem/Progenitor Cells Predicts Response and Outcome in Myelodysplastic Syndrome Patients Treated with AzacitidineParaskevi Miltiades, Ιoannis Kotsianidis, Eleftheria Lamprianidou et al.|Unknown|2023Cited by 0
Supplementary Table S1 from The Stat3/5 Signaling Biosignature in Hematopoietic Stem/Progenitor Cells Predicts Response and Outcome in Myelodysplastic Syndrome Patients Treated with AzacitidineParaskevi Miltiades, Ιoannis Kotsianidis, Eleftheria Lamprianidou et al.|Unknown|2023Cited by 0